Connect Biopharma Holdings Ltd (CNTB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN USG235491010
Connect Biopharma Holdings Ltd financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 64,000.00 USD |
| Operating income | -58.07 m USD |
| EBIT | -55.28 m USD |
| Net income | -55.48 m USD |
| Diluted EPS – continuing operations | -1.00 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
More stocks
- Ene Technology Inc (6243.TW)
- DMS Propertindo Tbk PT (KOTA.JK)
- PPI Inc (062970.KQ)
- Winpac Inc (097800.KQ)
- TSI Co. Ltd. (277880.KQ)
- Dogwood Therapeutics, Inc. (DWTX)
- Kaonmedia Co Ltd (078890.KQ)
- Aldeyra Therapeutics, Inc. (ALDX)
- Force MOS Technology Co., LTD. (4923.TWO)
- Poled (487580.KQ)
- Eltek Ltd (ELTK)
- Cytogen Inc (217330.KQ)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.